Publication: Tie2, a journey from normal angiogenesis to cancer and beyond
Authors
Martin, V. ; Liu, D. ; Fueyo, J. ; Gomez-Manzano, C.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
The tyrosine kinase receptor Tie2 was
initially identified as a specific vascular growth factor
that governed several properties of endothelial cells
under both physiological and pathological conditions. It
was subsequently found that angiopoietins, the natural
ligands of Tie2, modulate Tie2-dependent signaling,
which in turn regulates the survival and apoptosis of
endothelial cells, controls vascular permeability, and
regulates the capillary sprouting that occurs during
normal angiogenesis such as through development and
ovarian remodeling. Tie2 also seems to play a crucial
role in several vascular abnormalities, such as familial
venous malformations. Beyond its critical role in
angiogenesis, Tie2 also appears to maintain the longterm
population and quiescent status of hematopoietic
stem cells in the bone marrow stem cell niche. In cancer,
Tie2 was originally found to be overexpressed in
tumoral vessels. More recently, our laboratory and others
have found that Tie2 is also expressed outside the
vascular compartment in several types of cancer,
including leukemia and solid neoplasms such as gastric
tumors, breast tumors, and gliomas. The role of Tie2 in these tumoral cells is currently being explored. In this
regard, our group reported the importance of Tie2-
expressing glioma cells in their adhesion to the tumoral
microenvironment. Because cancer may be considered
as a complex organ with several cellular lineages
coexisting in the same tumor, the expression of Tie2 by
different tumoral compartments makes this cellular
receptor an attractive target for cancer therapy.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.